Mark:

CRI

Status Date:

04-01-2022

Registration Number:

N/A

Goods and Services:

Providing online non-downloadable electronic publications in the nature of newsletters, journals, and books in the field of cannabinoid-based medicines; arranging, conducting and organisation of educational conferences, congresses, seminars and symposiums in the field of cannabinoid-based medicines; information, advisory and consultancy services in relation to all of the aforesaid services Financing services; providing funding for investigators, inventors, universities, research institutes and other academic entities, namely, financing services and providing venture capital, development capital, private equity and investment funding; funding of research and product development, namely, financing services and providing venture capital, development capital, private equity and investment funding; information, advisory and consultancy services in relation to all of the aforesaid services Scientific and technological services and research and design relating thereto, namely, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services

Class:

Scientific and technological services

Published for Opposition Date:

N/A

Mark Drawing Status:

Standart Character Mark

Business Name:

WINTHROP & WEINSTINE, P.A.